Proceeds from the financing will enable Bactolife to advance its most mature projects towards commercial launch and strengthen the technology platform and upscaling capabilities. By doing so, the company aims at retaining its first mover advantage to transform human and animal health with target specific Binding Proteins.

The company intends to use the funds to expand R&D and clinical development efforts of its brain energetics products based on ketone bodies. KetoSwiss’ flagship product MigraKet a dietary-preventive therapy for migraine and related diseases that are characterized by metabolic dysfunction.

It is looking for innovative and sustainable ventures whose business integrates dimensions related to one or several of the three main pillars of sustainability, namely people, planet, and prosperity. The 14th edition of the program will provide the right tools and support to maximize the startup’s chances for commercial success in and out of Luxembourg. Fit 4 Start has dedicated tracks for healthtech and space startups.

The financing will help advance commercial operations driving adoption of the ECGenius System, the company’s innovative EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures. This includes expansion of the company’s sales team and U.S. presence, and further …

AATec Medical is developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT). It will use the funds to scale up its technology, expand the team and prepare for clinical studies expected to start in 2024. The first product candidate, ATL-105, is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.

The proceeds will enable OrganOx to significantly expand its commercial footprint across strategically key areas of the business. This includes expanding the customer-facing team in the United States due to high interest and adoption of the OrganOx technology. In addition, the investment will be made in new infrastructure to facilitate and accelerate programs within the R&D pipeline.

The round, which brought the total amount to €18M, saw participation from a combination of existing and new family office investors. Paris, France-based biotechnology company developing pinpoint DNA medicine solutions will use the funds to finance the clinical development of its lead product EG110A and advance other pipeline products.

Tenpoint Therapeutics is a biotechnology company that was established based on the pioneering work of its scientific founders from Moorfields Eye Hospital, University College London Institute of Ophthalmology, Institut de la Vision in Paris, and the University of Washington, who have developed engineered cell-based therapeutics and performed translational research to establish proof-of-concept. Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.

The company has developed an AI-powered prenatal screening solution that automates ultrasound reporting, ensuring healthy pregnancies worldwide. Sonio will use the funds to fuel improvements to the SaaS solution, initiate its commercial development in the United States, and adapt its technology for the use of portable ultrasound scanners “providing image quality control and detection of potential anomalies using AI.”

The Munich-based company raised €207 million ($225 million) on the back of a solid year of growth. EGYM’s business includes a line of connected hardware (gym equipment); software (apps and diagnostics to measure and optimize how people work out on connected fitness equipment); a corporate health network operation called Wellpass with more than 2.5 million users; and a mission: to improve healthcare outcomes by focusing on “the shared economy of a gym,” in the words of CEO and co-founder Philipp Roesch-Schlanderer.

The Swedish start-up, co-founded by Spotify’s founder, provides solutions for preventative healthcare using its non-invasive medical scanning technology concept. Neko Health claims its offering has been in huge demand in Sweden, where it sold out all the slots in less than two hours and has a waiting list of over 10,000 people. It will use the money to hire world-class talent, conduct clinical studies, and expand to other European markets.

Led by Mercia, the funding will be used to scale operations and continue the development of Camena’s pioneering DNA synthesis platform – gSynth. This unique and highly accurate enzyme-based DNA synthesis technology has helped the company sign commercial agreements with leading consumers of synthetic genes, securing a multi-million-pound revenue stream over the previous year.

This new investment will enable Gleamer to extend its portfolio of solutions to CT scans and mammography and cover 70% of radiologists’ daily needs. The company aims to accelerate its international expansion, particularly in Europe and the United States, where the sales teams will be strengthened. Gleamer will extend existing strategic partnerships while signing new large-scale partnerships to make Gleamer’s solutions accessible to as many people as possible.

Carthera will use the proceeds to launch the first pivotal multicenter trial with its SonoCloud, an innovative ultrasound-based medical device to treat a wide range of brain disorders. These funds will also enable it to continue developing its clinical pipeline and technology. Currently, the company is in the process of submitting its registration trial in recurrent glioblastoma (GBM) to the US FDA and EU competent authorities.

Europe’s healthcare systems are under mounting pressure as a result of the personnel shortage and growing healthcare demand. Innovation could provide a solution, but too few innovations make it to the market due to the lack of early-stage capital investments and expertise. The NLC Health Impact Fund addresses these gaps by providing early-stage capital to the most promising healthcare innovations. Specifically, it will deploy capital towards the first 40 ventures of varied maturity levels, providing initial and follow-on funding.

The company’s lead program, TGW101, is a click-cleavable ADC targeting tumor-associated glycoprotein 72 (TAG72), a clinically validated non-internalizing target widely expressed in solid tumors. TGW101 is designed to enable targeted and controlled drug release and activation in the tumor microenvironment, thus facilitating the killing of tumors with heterogenous target expression, which are difficult to treat with current therapies. The proceeds of the financing will support Tagworks in bringing this program towards initial clinical proof-of-concept, and in advancing the company’s broader pipeline, currently focused on oncology.

London-based VC firm Boost Capital Partners announced that it has successfully completed its first close of $30M. The firm invests in pre-seed and seed companies with initial ticket sizes of up to $750,000 and follow-on capabilities. It targets a broad range of sectors of the real economy where the user experience can be significantly improved, health being one of them. Boost Capital Partners has already backed 7 companies in geographies across Europe and Latin America.

The three-month program provides healthcare and well-being startups with essential growth skills, internationalization strategies, and Google tools and products to help them scale. It is a hybrid program that supports high-potential startups in Europe, Middle East, and Africa using AI technology to grow and innovate responsibly in the healthcare and well-being industry. The application deadline is July 10.

The company will use the funds to fuel the development and commercialization of its product as it plans to builds an extensive pathogen DNA library. Solu also has plans to build an extensive pathogen DNA library in order to prevent antibiotic resistance via “better research and faster identification.” The pathogen DNA library will collect all pathogen data in real-time and also model their evolution and identify new health-threatening pathogens more effectively.

The fintech for the patient facing medical sector will use the funds to accelerate its growth in Germany, develop additional products, deepen its fintech capabilities, as well as to expand into new medical verticals and markets. According to Nelly, using its solution could potentially reduce payment fees by 30% to 50% as its digital solution is significantly minimizing expenses related to invoice creation, postage fees, and the current elevated costs associated with factoring.

The Ready4OP app servers as a digital companion supporting patients preparing for major operations. Capreolos provides evidence based, scientifically sound information and useful facts about surgery and hospital stays. The Ready4OP app also provides a guide to questions for doctor-patient discussions. It is intended to help patients and their care givers to optimally prepare for the first consultation with their surgeon. In everyday medical practice, general practitioners and other non-surgical specialists are often unable to fully cover all the relevant information and provide this support to their patients.

Life5 works with several insurance companies and simplifies the subscription process. Customers can sign up in a few minutes through Life5’s website where they only need to fill out a form. The company’s underwriting engine can handle 700 illnesses and risk professions, which greatly increases the acceptance rate. The startup acts as a managing general agent and partners with insurers and reinsurers, such as Axa and CNP Assurances. At the moment, some 9,000 families are covered by a Life5 insurance product.

Founded in 2019, London-based GetHarley takes a fundamentally different approach to skin health. It matches customers with its one thousand-plus (and constantly growing) network of clinicians to offer skin consultations hosted on the GetHarley platform. Patients can share their concerns and goals, speak to a clinician and be recommended and sent a bespoke skincare routine of the best medical-grade products. This seamless experience improves the quality of service that clinicians can provide, and also helps to open up the sector to consumers who would otherwise get overwhelmed or do not know where to start. Index Ventures led the round.

The acquisition has strengthened Olympus’ recently announced strategy and initiatives in digital health and brings the promise of AI-powered real-time diagnosis and minimally invasive treatment of chronic diseases closer to reality, ultimately raising the standard of care across multiple medical specialties and improving patient outcomes.

By harnessing AI and clinical edge computing, the King’s College London spin-out aims to revolutionize surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties. The funding round was led by a syndicate of experienced European and American HealthTech investors, including HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures.

Lindus Health’s clinical trial software has been used in over 80 trials in the UK, US and Europe since beginning in 2021. Organizers of clinical trials can conduct study design, recruitment and delivery through the Lindus platform. The company is currently working with Pharmanovia on trials for insomnia and a digital tinnitus one with Oto.

The company wants to be something other than a little sleep tracker; it wants to be a health tracker and a general-purpose application in payments, identity, and security access. And it has taken steps in that direction, having acquired a digital identification startup, Proxy, to help it move into some of those new areas of business in the not-so-distant future…

Great Ormond Street Hospital for Children (GOSH) and Roche UK have partnered to harness the power of data by co-develop digital tools. The collaboration will develop the use of cutting-edge technologies, like artificial intelligence and machine learning to enable better use of data that is routinely collected in treatment to improve care for children and young people at GOSH and beyond.

While WHO is enthusiastic about the appropriate use of technologies, including LLMs, to support health-care professionals, patients, researchers and scientists, there is concern that caution that would normally be exercised for any new technology is not being exercised consistently with LLMs. This includes widespread adherence to key values of transparency, inclusion, public engagement, expert supervision, and rigorous evaluation…

Patient21, a four-year-old German startup that combines a digital healthcare platform with real-world brick-and-mortar clinics, has raised €100 million ($108 million) in a Series C round of funding led by Israeli VC firm Pitango, constituting a mix of equity and debt. Founded out of Berlin in 2019, Patient21’s platform spans pretty much the whole patient cycle, from online bookings through digital case histories, check-ins, billing, insurance and more.

Elkstone, a wealth management firm that for the past decade has invested privately at the seed stage in future unicorns such as Flipdish and LetsGetChecked, has launched its inaugural VC fund with the backing of the state’s Ireland Strategic Investment Fund (ISIF) and Enterprise Ireland (EI). The €100 million fund claims around 250 limited partners (LPs) in total, including a host of undisclosed business people from Ireland.

Lifeline Ventures typically invests at the angel and seed stage, with some follow-on investments in the Series A realm. While “angel” usually refers to wealthy individuals investing with their own cash, in this instance the company means that it sometimes backs companies at a super-early stage, before they have anything meaningful to show from a product perspective. Such investments have included mixed reality headset maker Varjo and smart ring maker Oura, which recently claimed a valuation of $2.55 billion.

Proxy’s digital identity signal technology, stored on mobile devices, replaces the multitude of keys, cards, badges, apps, and passwords and is designed to enhance data privacy in an increasingly decentralized world. Proxy has been in stealth mode, working to advance its biometrically-linked digital technology from mobile phones to wearables. As part of the acquisition, ŌURA will bring on key full-time employees from Proxy, including its founders.

DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Its lead program is focused on modulating the Wnt/β-catenin signaling pathway to regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development. Backers included Roche Venture Fund, Eli Lilly and Company, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund, and Adbio partners.

The global healthy eating platform Lifesum has unveiled a sleep tracking feature, which will allow its users to understand how their dietary choices impact their sleep patterns – and vice versa. The feature is made possible in partnership with Finland’s ŌURA, the company behind the smart ring that delivers personalized health data, insights, and daily guidance — and will build on their integration of Health Connect by Android to give Lifesum users another important layer of health data to track.

The company’s Biolytica NEXUS health data platform is dubbed a revolutionary AI-driven analytics platform that aggregates, visualizes and analyzes a whole raft of data — including genomics, blood, microbiome and epigenetic biomarkers, wearable devices, lifestyle data and more. Biolytica will use the funds to broaden its research and development efforts, scale its services to reach a wider client base and further collaborate with professionals in personalized and preventive healthcare.

The study, published in JAMA Internal Medicine, found that ChatGPT might actually be quite successful in providing high-quality, empathetic answers to patient questions during an era in which doctors and nurses are too busy to do so. John Ayers, a public health researcher at the University of California San Diego led the study, comparing two sets of written responses to real-world patient questions. One set was written by physicians, the other by ChatGPT. The patient questions were sourced from Reddit’s AskDocs subreddit.

The company has announced a €7m extension to its Series A led by the Singapore-based global VC MassMutual Ventures. The new capital will be used to increase the commercialization of HelloBetter’s digital therapeutics (DTx) products in Germany, as well as for further expanding in Europe and the United States.

Ciliatech is specialized in ophthalmology and its new class of implant designed to address the need to treat glaucoma durably and with zero adverse effects. The CID (Cilio-scleral Inter-positioning Device) implant aims to reduce intraocular pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration, thus overcoming serious complications and shortcomings of other glaucoma surgical techniques. As CID is inserted between only two areas of the eye (between the ciliary body and the sclera), it offers the advantage of unlocking the natural uveoscleral pathway without altering the anterior segment of the eye.

TympaHealt provides a solution that enables fully digitized assessments of ear and hearing health to be performed in both traditional and community-based clinical settings. The Tympa Platform allows a broad range of professionals to perform digital otoscopy, microsuction wax removal, and hearing assessments. The company intends to use the funds to grow its team and services in the UK, across Europe and enter into the US.

According to SkyQuest, the market’s growth will be significant due to factors such as the aging population, chronic diseases, government initiatives, cost-effectiveness, and technological advancements. Furthermore, the report states that Europe’s aging population is expected to exceed 150 million by 2050, leading to increased demand for home healthcare services as elderly individuals prefer to receive care at their own homes. The report also reveals that home healthcare services can reduce healthcare costs by up to 30% compared to hospitalization or institutional care.

Regulatory mandates encouraging the implementation of digital health strategies have increased EHR adoption, which has aided the growth of the patient portal market. The patient portal market has grown in popularity as a result of government agencies’ push for database interoperability and the ease of use provided by EHR in increasing patient engagement. Furthermore, as the number of projects in developing countries grows, so will the demand for patient portals.

The new fund, called Gilde Healthcare Venture&Growth VI, focuses on fast-growing companies developing solutions for better care at a lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics. The fund is backed by a balanced mix of international investors, including corporates, banks, pension funds, insurers, fund-of-funds, sovereign wealth funds, endowments, family offices, entrepreneurs and the Gilde team.

New investment comes from existing VC backers as the company configures for Series A funding. The successful close demonstrates ongoing confidence in Zetta Genomics and its transformational XetaBase platform – to unlock the improved research, medical and healthcare outcomes of genomics at scale.

According to the report published by Virtue Market Research, the Global Digital Behavioural Health Market was valued at $106.93 billion in 2022, and is projected to grow at a CAGR of 29% over the forecast period of 2023-2030. The increasing focus on patient empowerment and self-management is expected to drive the growth of the Digital Behavioural Health Market in Europe in the coming years.

Global mobile health apps market value is projected at $68.26 billion in 2023 and is expected to grow at a CAGR Of 18.1% by 2033. Europe is the second-largest market for mobile health apps, with countries like the United Kingdom, Germany and France leading the charge. This region boasts a high population of smartphone users, rising healthcare costs and an acute shortage of healthcare professionals – factors driving demand for these applications.

According to a new report by Grand View Research, digital health market is expected to expand at a CAGR of 18.6% during the forecast period. Rising smartphone adoption, improved internet connectivity with the launching of 4G/5G, advancement in healthcare IT infrastructure, rising healthcare costs, the rising penetration rate of chronic diseases, increasing adoption rate of remote patient monitoring services, and rising accessibility of virtual care are some of the major factors that fuel the industry growth.

Teton’s AI solution will give nurses the tools to monitor patients in real time and help them to stay on top of paperwork. The AI assistant acts as an extra pair of eyes and ears as smart cameras scan the wards for updates and patient activity, which is then fed back into a web app to update the nurses of any changes.

With the acquisition, Phlo is purchasing Truepill’s partnerships with several UK digital healthcare providers, such as The Lowdown, Levels, Daye, Hanx, and Veri as well as the company’s tech stack, including the full set of APIs and prescribing technology. Phlo Digital Pharmacy is currently available in Birmingham and London, and is expected to expand to Manchester later this year.

With this joint venture, customers of shop-apotheke.ch and Mediservice as well as new customers will benefit from the combined online pharmacy’s extensive offerings, which will include health and beauty products as well as prescription medications and healthcare services. The joint venture will operate under the name Mediservice AG with its registered office in Zuchwil (Switzerland, Canton Solothurn).

The five-year collaboration, backed by the French Government and called PortrAIt, will see the best research hospitals in France working alongside tech firms to develop a minimum of 15 AI-driven tools to enhance cancer diagnosis. They will then be tested and deployed in cancer centers and pathology labs across France.

Care.Chain provides a globally connected, open network architecture where all participants in the healthcare ecosystem can interact on a peer-to-peer basis in a transparent, trusted, and secure manner. The chain integrates seamlessly with the broader Solve.Care ecosystem and adds to the full-stack digital healthcare platform that simplifies the healthcare experience for all stakeholders which include individuals and families, doctors and care providers, employers, insurance providers, government agencies, and more.

Sofinnova Digital Medicine will back entrepreneurs innovating at the cutting edge of technology and biology and help them scale and become global leaders. Like all the funds on Sofinnova’s platform of strategies, Sofinnova Digital Medicine will focus on developing the most promising innovations that address systemic challenges in healthcare and can profoundly improve the lives of patients worldwide.

GoJoe is a hybrid consumer and B2B app that enables workplaces and brands to connect and engage their people. It combines wearables, content, and team-based challenges and experiences to socialize everyday solo exercise for the masses of “ordinary joes” and help people stick to their fitness and well-being journeys. The company collaborated with Stanford University on psychology, data, and gamification to build the app, which is used by brands including PwC, PayPal, Experian, and Amazon.

The Finnish medical imaging company aims to speed up the cancer treatment planning process while still delivering high-quality care. Its approach calls for AI-powered automatic segmentation tooling, which lets it streamline the all-important radiotherapy treatment planning workflow. Compared to manual treatment planning, which often requires two to three weeks of anxious waiting before radiotherapy treatment planning starts, MVision’s automation enables same-day treatment.

AERA Health’s hybrid model brings data-driven P4 medicine to consumers via existing healthcare infrastructure. P4 medicine focuses on future-oriented health plans, using data to foresee patient issues (predictive), acting to prevent rather than cure diseases (preventive), making tailored diagnoses and therapies (personalized), and including patients in decisions (participatory).

Founded out of Berlin in 2017, Medwing targets the healthcare industry in Germany and the U.K. with a platform designed to match hospitals and clinics with nurses and elderly caregivers, though it also caters to pharmacists, midwives, doctors and similar professionals. The platform is currently available in Germany and the U.K., where it claims some 5,500 registered medical employers and 500,000 healthcare professionals, who can access an entirely digital workflow spanning job search, contracts, signatures and timesheets.

The level of European investment has therefore continued to grow in 2022, albeit in a more measured way than between 2020 and 2021. 301 deals were closed, representing a 22% YoY increase in total financing. There are now 1000+ companies active in digital health across Europe today. In contrast, the level of investment in the US in digital health has dropped significantly, while Europe has been more stable in 2022.

The London-based healthtech startup will use the funds (Series B) to further expand its network of therapists, partners, and members across the UK and Continental Europe. Octopus Ventures led the round with the participation of existing investors Omers, Mantaray, and Oxford Capital.

Global Digital Therapeutics market is valued at $3.16 Billion in 2021 and is projected to attain a value of $14.52 Billion by 2028 at a CAGR of 28.1% during the forecast period, 2022–2028. The general public has become more conscious of the continuously shifting digital scene. Furthermore, the market is fueled by rising chronic disease prevalence and rapid technology improvements. End-user awareness is predicted to rise as a result of the use of digital devices and solutions, propelling the industry forward. Consumer attitudes toward digital health are predicted to continue to alter, as will their demand for accessible, personalized, and engaging medical solutions.

The two parties will work on developing Neos, a diagnostic device for the early diagnosis of brain disorders. Neos will be integrated with the Varjo Aero headset to enable a complete, standardized, and instrument-based neuro-ophthalmologic examination using the headset’s built-in VR-based eye-tracking solution. Varjo and machineMD stated that the development of Neos is advancing rapidly, with ongoing research studies at The University Hospital of Bern and several other clinics currently underway.

Now in its seventh consecutive year, the NHS-delivered programme, has supported 143 of the biggest and most effective digital innovations now being used by the NHS and social care, and many scaling globally. Examples include Huma, DrDoctor, Peppy Health, eConsult, Echo, AccuRx and HN. Over 600 additional contracts have been signed by companies during Accelerator support and the programme was also named Accelerator of the Year at the UKBAA Angel Investment Awards 2022.

Under the deal, Dawn Health will develop a platform that empowers patients and their care teams to make better and faster treatment decisions. By combining a patient mobile app focused on high engagement and exceptional UX with innovative elements like symptom tracking, novel (digital) biomarkers, clinical decision support services, virtual clinic capabilities and other relevant services as they become available – the platform will be tailored very specifically to the needs and demands of each separate disease in scope.

A hospital in Spain is launching a study to test the efficacy, tolerability, and acceptance of a drug produced for children using a 3D printer. The study results from collaboration between the Pharmacy Service at Vall d’Hebron University Hospital, the University of Santiago de Compostela, and the company FabRx. The 3D printer used for the study produces medicines in semi-solid and chewable forms, which are personalized to each child based on their weight and clinical characteristics.

Called Izar, it is an FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function. Izar is designed to fill a critical gap in neurological care today and aims to be the most effective hand dexterity and strength treatment in a wide range of neurological conditions. This proprietary peripheral is part of a comprehensive omnisite approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI), among others.

The new skin temperature-based cycle tracking capabilities will be available through the Samsung Health app on the Galaxy Watch5 and Watch5 Pro within the second quarter in 32 markets, which includes Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Korea, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, the U.K. and the U.S.

EPFL researchers have combined low-power chip design, machine learning algorithms, and soft implantable electrodes to produce NeuralTree, a closed-loop neuromodulation system-on-chip that can detect and alleviate symptoms of various neurological disorders.

Starting with the UK, the company now brings together Headspace’s world-class meditation and mindfulness offering with on-demand coaching, therapy and EAP services to provide a single mental health solution that reduces complexity, administrative burden and cost for employers. Headspace Health plans to extend these services into additional markets throughout 2023.

In this cohort study of 11 801 patients with OUD with commercial insurance or Medicare Advantage coverage, there were no significant differences in visit frequency, initiation of medications for OUD, or OUD-related adverse outcomes between those who were treated by clinicians with high vs low telemedicine use across the prepandemic and pandemic periods.

A new report by EIT Health InnoStars explores the state of digital therapeutics (DTx) and barriers in selected 6 EU countries. It also indicates 11 strategic recommendations for accelerating DTx in the EU.

This economic evaluation of cost savings from completed telehealth appointments included 11 688 patients younger than 65 years, with 25 496 telehealth visits at a National Cancer Institute–Designated Comprehensive Cancer Center from April 1, 2020, to June 30, 2021. According to cost models, the estimated mean total cost savings ranged from $147.4 to $186.1 per visit.